MwanzoJAZZ • NASDAQ
add
Jazz Pharmaceuticals PLC
Bei iliyotangulia
$ 166.71
Bei za siku
$ 166.09 - $ 169.25
Bei za mwaka
$ 95.49 - $ 182.99
Thamani ya kampuni katika soko
10.25B USD
Wastani wa hisa zilizouzwa
1.29M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 1.13B | 6.74% |
Matumizi ya uendeshaji wa biashara | 745.72M | 9.16% |
Mapato halisi | 251.41M | 16.91% |
Kiwango cha faida halisi | 22.33 | 9.57% |
Mapato kwa kila hisa | 8.13 | 23.00% |
EBITDA | 429.76M | 1.01% |
Asilimia ya kodi ya mapato | -2,697.20% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 2.05B | -21.85% |
Jumla ya mali | 11.36B | -7.34% |
Jumla ya dhima | 7.40B | -8.50% |
Jumla ya hisa | 3.96B | — |
hisa zilizosalia | 60.77M | — |
Uwiano wa bei na thamani | 2.56 | — |
Faida inayotokana na mali | 5.64% | — |
Faida inayotokana mtaji | 6.79% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 251.41M | 16.91% |
Pesa kutokana na shughuli | 474.62M | 19.03% |
Pesa kutokana na uwekezaji | -327.80M | -253.12% |
Pesa kutokana na ufadhili | -10.83M | -104.39% |
Mabadiliko halisi ya pesa taslimu | 136.19M | -84.21% |
Mtiririko huru wa pesa | 466.35M | 56.12% |
Kuhusu
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2003
Tovuti
Wafanyakazi
2,800
